12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Company News  |  Deals

Nanobiotix, PharmaEngine deal

Nanobiotix granted PharmaEngine exclusive rights to develop and commercialize NBTXR3 in the Asian-Pacific region. Nanobiotix will receive a $1 million upfront payment and is eligible for up to $56 million in milestone payments, plus double-digit royalties. Nanobiotix, which retains...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >